All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Focused on heart failure treatment according to the updated 2023 guidelines

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F24%3A10001254" target="_blank" >RIV/00064190:_____/24:10001254 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/24:10481943 RIV/00216208:11120/24:43927467

  • Result on the web

    <a href="https://doi.org/10.33678/cor.2024.025" target="_blank" >https://doi.org/10.33678/cor.2024.025</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.33678/cor.2024.025" target="_blank" >10.33678/cor.2024.025</a>

Alternative languages

  • Result language

    čeština

  • Original language name

    Zaostřeno na léčbu srdečního selhání dle inovace guidelines 2023

  • Original language description

    Acute and chronic heart failure remains a very serious and high priority problem in contemporary cardiology. New, modern drugs are currently emerging in the treatment of heart failure while the possibilities of their further use for this diagnosis are being expanded. These findings have been summarized in the 2023 update of the European Society of Cardiology Guidelines for heart failure. This article provides a brief summary of the new developments in pharmacotherapy based on the above recommendations. (C) 2024, ČKS.

  • Czech name

    Zaostřeno na léčbu srdečního selhání dle inovace guidelines 2023

  • Czech description

    Acute and chronic heart failure remains a very serious and high priority problem in contemporary cardiology. New, modern drugs are currently emerging in the treatment of heart failure while the possibilities of their further use for this diagnosis are being expanded. These findings have been summarized in the 2023 update of the European Society of Cardiology Guidelines for heart failure. This article provides a brief summary of the new developments in pharmacotherapy based on the above recommendations. (C) 2024, ČKS.

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30201 - Cardiac and Cardiovascular systems

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2024

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    COR ET VASA

  • ISSN

    0010-8650

  • e-ISSN

    1803-7712

  • Volume of the periodical

    66

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    CZ - CZECH REPUBLIC

  • Number of pages

    7

  • Pages from-to

    105-111

  • UT code for WoS article

    001232161500002

  • EID of the result in the Scopus database

    2-s2.0-85192020245